Clinical Chemistry and Blood Coagulation

Denna sida på svenska

Members of the group

Postdoc

Mikel Allend

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: mikel.allend@ki.se

Lecturer senior, adjunct

Jovan Antovic

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: jovan.antovic@ki.se

Professor, senior

Magnus Axelson

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Magnus.Axelson@ki.se

Professor emerita

Margareta Blombäck

Phone: +46-(0)8-517 744 37
Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Margareta.Blomback@ki.se

Laboratory engineer

Benziane Boubacar

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Boubacar.Benziane@ki.se

Senior researcher

Lynn Butler

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: lynn.butler@ki.se

Postdoc

Roza Chaireti

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: roza.chaireti@ki.se

Senior Lecturer

Tore Curstedt

Phone: +46-(0)8-517 760 82
Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: tore.curstedt@ki.se

Assistant professor

Antonio Di Gennaro

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Antonio.Di.Gennaro@ki.se

PhD student

Maria Farm

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: maria.farm@ki.se

Senior researcher

Tobias Fuchs

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: tobias.fuchs@ki.se

Associated

Sven Gustafsson

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: sven.gustafsson@ki.se

Biomedical scientist

Marie Haegerstrand-Björkman

Phone: +46-(0)8-517 761 63
Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Marie.Haegerstrand-Bjorkman@ki.se

Senior lab manager

Anne Jämsä

Phone: +46-(0)8-517 735 65
Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Anne.Jamsa@ki.se

Senior Lecturer

Anders Kallner

Phone: +46-(0)8-517 749 43
Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Anders.Kallner@ki.se

Associated

Magnus Larsson

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: magnus.larsson@ki.se

Postdoc

Maria Magnusson

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Maria.Magnusson@ki.se

Associated

Aleksandra Mandic Havelka

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: aleksandra.mandic.havelka@ki.se

Postdoc

Clément Naudin

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: clement.naudin@ki.se

Postdoc

Zara Pons Vila

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: zara.pons.vila@ki.se

Professor/senior physician

Thomas Renné

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: Thomas.Renne@ki.se

Associated

Åsa Sandin

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: asa.sandin@ki.se

Associated

Annelie Strålfors

Phone: +46-(0)8-517 706 47
Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: annelie.stralfors@ki.se

PhD student

Yanan Zong

Organizational unit: Clinical Chemistry and Blood Coagulation Research
E-mail: yanan.zong@ki.se

Associates

Postdoc

Leonardo Gottlob

E-mail: leonardo.gottlob@scilifelab.se

Postdoc

Philip Busart

E-mail: philip.dusart@scilifelab.se

Research focus

Combinations of proinflammatory and procoagulant reactions are the unifying principle for a variety of thrombotic disorders affecting the cardiovascular system. Thrombosis - localized clotting of the blood - may occur in the arterial or the venous circulation and has a major medical impact. Acute arterial thrombosis is the proximal cause of most cases of myocardial infarction (heart attack) and of about 80% of strokes, collectively the most common cause of death in the developed world.

Factor XII (FXII, Hageman factor) is a plasma protease that initiates the contact system. This system starts a cascade of procoagulant and proinflammatory reactions via the intrinsic pathway of coagulation, and the bradykinin-producing kallikrein-kinin system, respectively (Figure 1). The biochemistry of the contact system in vitro is well understood, however its in vivo functions are just beginning to emerge.

We have previously demonstrated that FXII is essential for thrombus formation while being dispensable for hemostatic processes that terminate blood loss. Challenging the dogma of a coagulation balance, targeting factor XII protected from cerebral ischemia without interfering with hemostasis. In contrast, excess FXII activity is associated with a life threatening inflammatory disorder, Hereditary angioedema. We recently have identified platelet polyphosphate (an inorganic polymer) and mast cell heparin as in vivo FXII activators with implications on the initiation of thrombosis and edema.

A key aspect of our work is the analysis of common principles, and cross-talk between coagulation and inflammation, to establish new biomarkers and bioassays and to identify novel therapeutic targets. 

The factor XII (FXII)-driven contact system

Figure 1: The factor XII (FXII)-driven contact system. Contact with negatively charged surfaces activates coagulation factor XII (FXII) on leukocytes, bacteria, endothelial cells, and thrombocytes and initiates pro-coagulant and pro-inflammatory protease cascades. FXII triggers fibrin formation through the factor XI (FXI)-driven intrinsic pathway of blood coagulation. Activated FXII initiates the kallikrein-kinin system that generates the pro-inflammatory peptide hormone bradykinin by plasma kallikrein (PK)-mediated cleavage of high molecular weight kininogen (HK). BK triggers intracellular signaling events that increase vascular leakage by Ena/VASP-mediated rearrangements of the endothelial cytoskeleton.

The FXII-driven contact system provides an excellent platform to test basic principles of coagulation and inflammation with new perspectives to improve diagnostics and therapies of thrombotic, inflammatory, infectious and allergic diseases. Insight into contact system functions offers the unique opportunity to develop "safe anticoagulant drugs" that interfere with thrombosis and lack the bleeding risk of all currently used anticoagulant medications. FXII inhibitors will also have beneficial anti-inflammatory potency and block edema formation with crucial clinical implications.

Current projects

  1. Crosstalk of coagulation and inflammation 
  2. Mechanisms, diagnostics and therapy of Hereditary angioedema
  3. Therapeutics, functions and diagnostics of the prothrombotic and proinflammatory FXII-driven contact system
Research area Group leader
Cholestorol metabolism Magnus Axelson
Surfactant Tore Curstedt
Contact activation system Katrin Nickel
Fibrin and Fibrin meshworks Margareta Blombäck
Quality control Anders Kallner
Hemostasiological diagnostics Jovan Antovic
Neutrophil Extracellular Traps (NETS)          Tobias Fuchs
Endothelial System Biology Lynn Butler

Selected publications (Top 10)

Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.
Labberton L, Kenne E, Long A, Nickel K, Di Gennaro A, Rigg R, et al
Nat Commun 2016 Sep;7():12616

Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III.
Björkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schönig K, et al
J. Clin. Invest. 2015 Aug;125(8):3132-46

The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.
Nickel K, Ronquist G, Langer F, Labberton L, Fuchs T, Bokemeyer C, et al
Blood 2015 Sep;126(11):1379-89

Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions.
Sala-Cunill A, Björkqvist J, Senter R, Guilarte M, Cardona V, Labrador M, et al
J. Allergy Clin. Immunol. 2015 Apr;135(4):1031-43.e6

Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma.
Zamolodchikov D, Chen Z, Conti B, Renné T, Strickland S
Proc. Natl. Acad. Sci. U.S.A. 2015 Mar;112(13):4068-73

A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.
Larsson M, Rayzman V, Nolte M, Nickel K, Björkqvist J, Jämsä A, et al
Sci Transl Med 2014 Feb;6(222):222ra17

Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo.
Oschatz C, Maas C, Lecher B, Jansen T, Björkqvist J, Tradler T, et al
Immunity 2011 Feb;34(2):258-68

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.
Müller F, Mutch N, Schenk W, Smith S, Esterl L, Spronk H, et al
Cell 2009 Dec;139(6):1143-56

Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.
Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer H, Burfeind P, et al
J. Exp. Med. 2006 Mar;203(3):513-8

Defective thrombus formation in mice lacking coagulation factor XII.
Renné T, Pozgajová M, Grüner S, Schuh K, Pauer H, Burfeind P, et al
J. Exp. Med. 2005 Jul;202(2):271-81